TrialReader


Phase 2 Safety and Efficacy Study of Bevirimat Functional Monotherapy in HIV Treatment-Experienced Patients for 2 Weeks*

NCT00511368 — Phase 2, Completed, 92 participants, Myrexis Inc.

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

Phase 2 Dose-escalating, P-C, D-B, Parallel Group Study in HIV Treatment-experienced Patients to Evaluate the Safety, Tolerability and Efficacy of PA103001-04 Administered as Functional Monotherapy for 14 Days *(PART B)

RegistryNCT00511368
StatusCompleted
PhasePhase 2
Study typeInterventional; randomized, single group, masking: double, treatment
Enrollment92 (Actual)
SponsorMyrexis Inc. (Industry)
ConditionsHIV Infections
Interventionsmatching placebo, Bevirimat (Drug)
Datesstart 2006-04-01, primary completion 2008-07-01, completion 2008-07-01, first posted 2007-08-03, last updated 2010-01-20
Locations18 sites in United States

Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for HIV Infections All trials of matching placebo All trials of Bevirimat

-Summary

The purpose of this study is to evaluate antiretroviral activity of up to five different oral doses administered for two weeks of bevirimat versus placebo in HIV treatment experienced patients, who have documented genotypic resistance to at least one major mutation from the IAS-USA list (2007)of resistance mutations for NRTIs, NNRTIs, or PIs. Patients will also be monitored for side effects, and the pharmacokinetics of bevirimat will be determined.

Expand all sections  ·  Collapse all

+Detailed description

Bevirimat (PA103001-04) represents a new class of antivirals that blocks HIV replication by disrupting virus maturation; specifically, by inhibiting a late step in the Gag processing cascade. Short term (7-10 days) functional monotherapy studies (conducted in patients with detectable viral loads on a failing regimen)help in determining the potency of the drug, and enable dose finding. This is a two part (A and B)randomized, placebo-controlled, double-blind, multiple-dose, dose-escalation study in HIV treatment-experienced patients on a failing regimen (harboring resistance mutations to at least one member of the NRTI, NNRTI or PI classes. The antiretroviral activity, safety, and pharmacokinetics of up to 5 different dose levels of bevirimat will be compared to placebo when added to a failing approved antiretroviral regimen. The study is conducted in two parts: A and B. In Part A following 14 days of daily dosing patients commenced a new optimized ART regimen in addition to their randomized treatment. In Part Part B dosing with the randomized treatment ends after the initial 14 days of daily dosing.

+Arms and interventions

ArmTypeInterventionsDescription
1Placebo comparatorDrug: matching placeboplacebo
2ExperimentalDrug: matching placebo; Drug: BevirimatBevirimat
  • matching placebo (Drug), also known as PA103001-04, PA-457N
  • Bevirimat (Drug)

+Outcome measures

Primary outcomes

  • HIV-1 RNA change from baseline over the first 14 days of study [14 days]

Secondary outcomes

  • safety and tolerability; pharmacokinetics [14 days]

+Eligibility

Sex: All, ages: 18 Years to 65 Years

Inclusion Criteria:

* Male or female. Females of child-bearing potential, must have a documented negative pregnancy test and be willing to utilize double-barrier contraception through-out the study period.
* Have HIV-1-infection.
* Have a screening plasma HIV-1 RNA value, measured by the Roche Amplicor assay, of 2,000 - 250,000 copies/ml (inclusive).
* Have documented evidence of genotypic resistance in their medical records (at screening) or have resistance at screening by genotype to any major mutation from the IAS-USA list of resistance drug mutations, defined as: NRTI resistance: M41L, K65R, D67N, K70R, K70E, L74V, Y115F, M184V, M184V/I, L210W, T215Y/F, K219Q/E; NNRTI resistance: L100I, K103N, V106M, V106A/M, V108I, Y181C, Y181C/I, Y188L, Y188C/L/H, G190S/A, G190A, P225H; Major PI resistance: D30N, V32I, L33F, M46I/L, I47V/A, G48V, I50L, I50V, I54M/L, L76V, V82A/F/T, V82A/F/T/S, V82L/T, I84V, N88S, L90M
* Be receiving an antiretroviral therapy regimen containing at least 3 drugs (regimens containing ritonavir must not exceed a total daily dose of 400 mg) which has been unchanged for at least 8 weeks prior to initial screening.
* Be able to receive an optimized background regimen.
* Be free from any acute infection or serious medical illness within 14 days prior to study entry.
* Be informed of the nature of the study and provide written informed consent.
* Be willing to comply with the meal requirements described in the protocol.

Exclusion Criteria:

* Current opportunistic infection characteristic of AIDS
* Patients unable or unwilling to comply with the dosing schedule and protocol evaluations.
* Patients with malabsorption syndromes affecting drug absorption.
* Patients with systolic blood pressure < 90 mmHg or > 140 mmHg or diastolic blood pressure < 60 mmHg or > 90 mmHg measured in a semi-recumbent position after at least 10 minutes of rest at the screening or qualification visit.
* A history of seizures (excluding pediatric febrile seizures), migraines, cluster and/or chronic headaches, cerebrovascular accident (CVA) or transient ischemic attacks (TIA).
* Patients with abnormal Hemoglobin (< 10.0 g/dL for men and < 9.0 g/dL for women), Neutrophil count (< 1000/mm3), Platelet count (< 100,000/mm3), AST or ALT > 2.5 times the upper limit of normal (patients with a positive HBV surface antigen or HCV antibody test at screening must have AST and ALT no more than 1.5 times the upper limit of normal)
* Patients who have received radiation therapy or cytotoxic chemotherapeutic agents, immunomodulating agents, HIV immunotherapeutic vaccine, an investigational drug or product, or participation in a drug study within 4 weeks prior to the first dose of study drug.
* A history of alcoholism or drug addiction within the past 1 year (unless enrolled in a treatment program and approved by the sponsor). Recent use of any recreational drugs (except marijuana).
* A history of difficulty donating blood or inadequate venous access.
* The donation of blood or plasma within 30 days prior to receiving study medication.

Note: patients with a CD4 count <100 cells/mm3 will be considered for enrollment following discussion and agreement between the Investigator and the Sponsor.

+Locations (18)

FacilityCityCountryStatus
UCLA Medical CenterLos Angeles, CaliforniaUnited States
Quest Clinical ResearchSan Francisco, CaliforniaUnited States
University of Colorado Health Science CenterDenver, ColoradoUnited States
George Washington University Medical CenterWashington D.C., District of ColumbiaUnited States
Whitman-Walker ClinicWashington D.C., District of ColumbiaUnited States
Gary RichmondFort Lauderdale, FloridaUnited States
Orlando Immunology CenterOrlando, FloridaUnited States
AIDS Research Consortium of Atlanta, Inc.Atlanta, GeorgiaUnited States
Northwestern University Feinberg School of MedicineChicago, IllinoisUnited States
The Research InsituteBoston, MassachusettsUnited States
UNC at Chapel HillChapel Hill, North CarolinaUnited States
University Hospitals of ClevelandCleveland, OhioUnited States
Ohio State University Medical CenterColumbus, OhioUnited States
Drexel University College of MedicinePhiladelphia, PennsylvaniaUnited States
Miriam Hospital/Brown UniversityProvidence, Rhode IslandUnited States
Central Texas Clinical ResearchAustin, TexasUnited States
Southwest Infectious DiseasesDallas, TexasUnited States
University of Texas Medical Branch Internal MedicineGalveston, TexasUnited States

+Investigators

My Notes